Intrinsic value of Glaukos - GKOS

Previous Close

$28.55

  Intrinsic Value

$109.86

stock screener

  Rating & Target

str. buy

+285%

Previous close

$28.55

 
Intrinsic value

$109.86

 
Up/down potential

+285%

 
Rating

str. buy

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of GKOS stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  58.33
  33.30
  30.47
  27.92
  25.63
  23.57
  21.71
  20.04
  18.54
  17.18
  15.96
  14.87
  13.88
  12.99
  12.19
  11.47
  10.83
  10.24
  9.72
  9.25
  8.82
  8.44
  8.10
  7.79
  7.51
  7.26
  7.03
  6.83
  6.65
  6.48
  6.33
Revenue, $m
  114
  152
  198
  254
  319
  394
  479
  575
  682
  799
  927
  1,064
  1,212
  1,370
  1,537
  1,713
  1,898
  2,093
  2,296
  2,509
  2,730
  2,960
  3,200
  3,449
  3,708
  3,977
  4,257
  4,548
  4,850
  5,164
  5,491
Variable operating expenses, $m
 
  45
  59
  76
  95
  117
  143
  171
  203
  238
  276
  317
  361
  408
  458
  510
  566
  624
  684
  748
  813
  882
  954
  1,028
  1,105
  1,185
  1,269
  1,355
  1,445
  1,539
  1,636
Fixed operating expenses, $m
 
  90
  92
  95
  97
  100
  102
  105
  107
  110
  113
  115
  118
  121
  124
  127
  131
  134
  137
  141
  144
  148
  151
  155
  159
  163
  167
  171
  176
  180
  185
Total operating expenses, $m
  110
  135
  151
  171
  192
  217
  245
  276
  310
  348
  389
  432
  479
  529
  582
  637
  697
  758
  821
  889
  957
  1,030
  1,105
  1,183
  1,264
  1,348
  1,436
  1,526
  1,621
  1,719
  1,821
Operating income, $m
  4
  16
  47
  83
  127
  177
  234
  299
  371
  451
  538
  632
  733
  840
  954
  1,075
  1,202
  1,335
  1,475
  1,620
  1,772
  1,930
  2,095
  2,266
  2,444
  2,629
  2,821
  3,021
  3,229
  3,445
  3,670
EBITDA, $m
  9
  20
  51
  89
  134
  186
  246
  313
  388
  470
  560
  657
  761
  872
  991
  1,115
  1,247
  1,385
  1,529
  1,680
  1,837
  2,000
  2,170
  2,347
  2,531
  2,723
  2,922
  3,128
  3,343
  3,567
  3,800
Interest expense (income), $m
  0
  0
  0
  0
  1
  1
  1
  2
  2
  3
  4
  4
  5
  6
  7
  7
  8
  9
  10
  11
  12
  14
  15
  16
  17
  19
  20
  22
  23
  25
  26
Earnings before tax, $m
  5
  16
  47
  83
  126
  176
  233
  297
  369
  448
  534
  627
  728
  834
  948
  1,068
  1,194
  1,326
  1,464
  1,609
  1,760
  1,917
  2,080
  2,250
  2,427
  2,610
  2,801
  2,999
  3,206
  3,420
  3,644
Tax expense, $m
  0
  4
  13
  22
  34
  47
  63
  80
  100
  121
  144
  169
  196
  225
  256
  288
  322
  358
  395
  434
  475
  518
  562
  607
  655
  705
  756
  810
  866
  924
  984
Net income, $m
  5
  12
  34
  60
  92
  128
  170
  217
  269
  327
  390
  458
  531
  609
  692
  779
  871
  968
  1,069
  1,175
  1,285
  1,399
  1,518
  1,642
  1,771
  1,905
  2,045
  2,190
  2,340
  2,497
  2,660

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  96
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  134
  51
  66
  85
  106
  131
  160
  192
  227
  266
  309
  355
  404
  457
  512
  571
  633
  698
  765
  836
  910
  987
  1,067
  1,150
  1,236
  1,326
  1,419
  1,516
  1,617
  1,721
  1,830
Adjusted assets (=assets-cash), $m
  38
  51
  66
  85
  106
  131
  160
  192
  227
  266
  309
  355
  404
  457
  512
  571
  633
  698
  765
  836
  910
  987
  1,067
  1,150
  1,236
  1,326
  1,419
  1,516
  1,617
  1,721
  1,830
Revenue / Adjusted assets
  3.000
  2.980
  3.000
  2.988
  3.009
  3.008
  2.994
  2.995
  3.004
  3.004
  3.000
  2.997
  3.000
  2.998
  3.002
  3.000
  2.998
  2.999
  3.001
  3.001
  3.000
  2.999
  2.999
  2.999
  3.000
  2.999
  3.000
  3.000
  2.999
  3.001
  3.001
Average production assets, $m
  14
  18
  23
  30
  38
  46
  57
  68
  80
  94
  109
  126
  143
  162
  181
  202
  224
  247
  271
  296
  322
  349
  378
  407
  438
  469
  502
  537
  572
  609
  648
Working capital, $m
  103
  9
  12
  15
  19
  24
  29
  35
  42
  49
  57
  65
  74
  84
  94
  104
  116
  128
  140
  153
  167
  181
  195
  210
  226
  243
  260
  277
  296
  315
  335
Total debt, $m
  0
  6
  13
  21
  30
  42
  54
  69
  85
  102
  121
  142
  164
  187
  212
  238
  266
  295
  325
  357
  390
  424
  460
  497
  536
  576
  617
  661
  706
  752
  801
Total liabilities, $m
  17
  23
  30
  38
  47
  59
  71
  86
  102
  119
  138
  159
  181
  204
  229
  255
  283
  312
  342
  374
  407
  441
  477
  514
  553
  593
  634
  678
  723
  769
  818
Total equity, $m
  117
  28
  37
  47
  59
  73
  88
  106
  126
  147
  171
  196
  223
  252
  283
  316
  350
  386
  423
  462
  503
  546
  590
  636
  684
  733
  785
  838
  894
  952
  1,012
Total liabilities and equity, $m
  134
  51
  67
  85
  106
  132
  159
  192
  228
  266
  309
  355
  404
  456
  512
  571
  633
  698
  765
  836
  910
  987
  1,067
  1,150
  1,237
  1,326
  1,419
  1,516
  1,617
  1,721
  1,830
Debt-to-equity ratio
  0.000
  0.200
  0.340
  0.440
  0.520
  0.570
  0.620
  0.650
  0.670
  0.690
  0.710
  0.720
  0.730
  0.740
  0.750
  0.750
  0.760
  0.760
  0.770
  0.770
  0.770
  0.780
  0.780
  0.780
  0.780
  0.790
  0.790
  0.790
  0.790
  0.790
  0.790
Adjusted equity ratio
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  5
  12
  34
  60
  92
  128
  170
  217
  269
  327
  390
  458
  531
  609
  692
  779
  871
  968
  1,069
  1,175
  1,285
  1,399
  1,518
  1,642
  1,771
  1,905
  2,045
  2,190
  2,340
  2,497
  2,660
Depreciation, amort., depletion, $m
  5
  4
  5
  6
  8
  9
  11
  14
  16
  19
  22
  25
  29
  32
  36
  40
  45
  49
  54
  59
  64
  70
  76
  81
  88
  94
  100
  107
  114
  122
  130
Funds from operations, $m
  6
  16
  39
  66
  99
  138
  181
  231
  285
  346
  412
  483
  560
  641
  728
  820
  916
  1,017
  1,123
  1,234
  1,349
  1,469
  1,594
  1,724
  1,859
  1,999
  2,145
  2,297
  2,455
  2,619
  2,790
Change in working capital, $m
  -6
  2
  3
  3
  4
  5
  5
  6
  7
  7
  8
  8
  9
  10
  10
  11
  11
  12
  12
  13
  14
  14
  15
  15
  16
  16
  17
  18
  18
  19
  20
Cash from operations, $m
  12
  13
  36
  63
  95
  133
  176
  225
  279
  339
  404
  475
  551
  632
  718
  809
  905
  1,005
  1,111
  1,221
  1,335
  1,455
  1,579
  1,709
  1,843
  1,983
  2,128
  2,279
  2,436
  2,600
  2,770
Maintenance CAPEX, $m
  0
  -3
  -4
  -5
  -6
  -8
  -9
  -11
  -14
  -16
  -19
  -22
  -25
  -29
  -32
  -36
  -40
  -45
  -49
  -54
  -59
  -64
  -70
  -76
  -81
  -88
  -94
  -100
  -107
  -114
  -122
New CAPEX, $m
  -6
  -4
  -5
  -7
  -8
  -9
  -10
  -11
  -13
  -14
  -15
  -16
  -17
  -19
  -20
  -21
  -22
  -23
  -24
  -25
  -26
  -27
  -28
  -29
  -31
  -32
  -33
  -34
  -36
  -37
  -39
Cash from investing activities, $m
  -26
  -7
  -9
  -12
  -14
  -17
  -19
  -22
  -27
  -30
  -34
  -38
  -42
  -48
  -52
  -57
  -62
  -68
  -73
  -79
  -85
  -91
  -98
  -105
  -112
  -120
  -127
  -134
  -143
  -151
  -161
Free cash flow, $m
  -14
  6
  27
  52
  82
  117
  157
  202
  253
  309
  370
  437
  508
  585
  666
  752
  843
  938
  1,037
  1,142
  1,250
  1,363
  1,481
  1,604
  1,731
  1,864
  2,001
  2,144
  2,293
  2,448
  2,609
Issuance/(repayment) of debt, $m
  -10
  6
  7
  8
  10
  11
  13
  14
  16
  17
  19
  21
  22
  23
  25
  26
  28
  29
  30
  32
  33
  34
  36
  37
  39
  40
  42
  43
  45
  47
  49
Issuance/(repurchase) of shares, $m
  8
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -2
  6
  7
  8
  10
  11
  13
  14
  16
  17
  19
  21
  22
  23
  25
  26
  28
  29
  30
  32
  33
  34
  36
  37
  39
  40
  42
  43
  45
  47
  49
Total cash flow (excl. dividends), $m
  -15
  12
  34
  60
  91
  128
  169
  216
  269
  326
  389
  457
  530
  608
  691
  778
  870
  967
  1,068
  1,173
  1,283
  1,398
  1,517
  1,641
  1,770
  1,904
  2,043
  2,188
  2,338
  2,495
  2,658
Retained Cash Flow (-), $m
  -22
  -7
  -9
  -10
  -12
  -14
  -16
  -18
  -20
  -22
  -24
  -25
  -27
  -29
  -31
  -32
  -34
  -36
  -37
  -39
  -41
  -42
  -44
  -46
  -48
  -50
  -52
  -54
  -56
  -58
  -60
Prev. year cash balance distribution, $m
 
  96
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  101
  25
  50
  79
  114
  154
  199
  249
  305
  366
  432
  503
  579
  660
  746
  836
  931
  1,030
  1,134
  1,242
  1,355
  1,473
  1,595
  1,722
  1,854
  1,991
  2,134
  2,283
  2,437
  2,598
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  97
  23
  43
  65
  88
  112
  134
  156
  175
  192
  205
  215
  220
  222
  219
  212
  203
  190
  175
  158
  140
  122
  105
  88
  72
  58
  46
  35
  27
  20
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm's canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream. It is developing three additional pipeline products: the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is a drug delivery system that is designed to be implanted in the eye to continuously deliver therapeutic levels of medication for extended periods of time to lower intraocular pressure in glaucoma patients.

FINANCIAL RATIOS  of  Glaukos (GKOS)

Valuation Ratios
P/E Ratio 193.8
Price to Sales 8.5
Price to Book 8.3
Price to Tangible Book
Price to Cash Flow 80.7
Price to Free Cash Flow 161.5
Growth Rates
Sales Growth Rate 58.3%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -62.5%
Cap. Spend. - 3 Yr. Gr. Rate 43.1%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets 4%
Ret/ On Assets - 3 Yr. Avg. -28.3%
Return On Total Capital 4.5%
Ret/ On T. Cap. - 3 Yr. Avg. -31.3%
Return On Equity 4.7%
Return On Equity - 3 Yr. Avg. -60.9%
Asset Turnover 0.9
Profitability Ratios
Gross Margin 86%
Gross Margin - 3 Yr. Avg. 80.6%
EBITDA Margin 8.8%
EBITDA Margin - 3 Yr. Avg. -18.9%
Operating Margin 3.5%
Oper. Margin - 3 Yr. Avg. -24.9%
Pre-Tax Margin 4.4%
Pre-Tax Margin - 3 Yr. Avg. -26.3%
Net Profit Margin 4.4%
Net Profit Margin - 3 Yr. Avg. -24.4%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

GKOS stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the GKOS stock intrinsic value calculation we used $114 million for the last fiscal year's total revenue generated by Glaukos. The default revenue input number comes from 2016 income statement of Glaukos. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our GKOS stock valuation model: a) initial revenue growth rate of 33.3% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for GKOS is calculated based on our internal credit rating of Glaukos, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Glaukos.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of GKOS stock the variable cost ratio is equal to 29.8%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $88 million in the base year in the intrinsic value calculation for GKOS stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Glaukos.

Corporate tax rate of 27% is the nominal tax rate for Glaukos. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the GKOS stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for GKOS are equal to 11.8%.

Life of production assets of 2.7 years is the average useful life of capital assets used in Glaukos operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for GKOS is equal to 6.1%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $117 million for Glaukos - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 35.104 million for Glaukos is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Glaukos at the current share price and the inputted number of shares is $1.0 billion.

RELATED COMPANIES Price Int.Val. Rating
STAA Staar Surgical 15.90 0.21  str.sell
IRIX Iridex 7.57 1.33  str.sell
EYES Second Sight M 1.88 0.05  str.sell
ABT Abbott Laborat 59.07 400.89  str.buy
NVS Novartis ADR 86.41 39.03  str.sell
RTIX RTI Surgical 4.40 1.98  str.sell

COMPANY NEWS

▶ ETFs with exposure to Glaukos Corp. : December 26, 2017   [Dec-26-17 11:34AM  Capital Cube]
▶ Why SCANA, Glaukos, and Juno Therapeutics Slumped Today   [Dec-11-17 04:30PM  Motley Fool]
▶ ETFs with exposure to Glaukos Corp. : November 16, 2017   [Nov-16-17 11:38AM  Capital Cube]
▶ Glaukos beats Street 3Q forecasts   [Nov-07-17 07:03PM  Associated Press]
▶ Glaukos Corp to Host Earnings Call   [10:00AM  ACCESSWIRE]
▶ ETFs with exposure to Glaukos Corp. : October 16, 2017   [Oct-16-17 09:53AM  Capital Cube]
▶ Should You Be Holding Glaukos Corporation (GKOS) Right Now?   [Oct-03-17 05:06PM  Simply Wall St.]
▶ ETFs with exposure to Glaukos Corp. : October 2, 2017   [Oct-02-17 10:51AM  Capital Cube]
▶ Here's Why Glaukos Corp. Stock Is Stumbling Today   [Sep-14-17 12:07PM  Motley Fool]
▶ IBD Rating Upgrades: Glaukos Flashes Improved Price Strength   [Sep-08-17 03:00AM  Investor's Business Daily]
▶ Glaukos Announces 2017 Investor Day and Webcast   [Aug-31-17 07:00AM  Business Wire]
▶ Glaukos reports 2Q loss   [Aug-04-17 03:17AM  Associated Press]
▶ Here's What's Pressuring Glaukos Corp Stock Today   [Aug-03-17 01:17PM  Motley Fool]
▶ Glaukos Corp. Value Analysis (NYSE:GKOS) : August 1, 2017   [Aug-01-17 06:27PM  Capital Cube]
▶ ETFs with exposure to Glaukos Corp. : July 24, 2017   [Jul-24-17 04:08PM  Capital Cube]
▶ ETFs with exposure to Glaukos Corp. : July 11, 2017   [Jul-11-17 02:34PM  Capital Cube]
▶ ETFs with exposure to Glaukos Corp. : June 30, 2017   [Jun-30-17 02:57PM  Capital Cube]
▶ ETFs with exposure to Glaukos Corp. : June 19, 2017   [Jun-19-17 03:24PM  Capital Cube]
▶ 3 Growth Stocks for Bold Investors   [Jun-10-17 02:06PM  Motley Fool]
▶ Which Stocks Are Showing Rising Relative Strength?   [May-24-17 12:05PM  Investor's Business Daily]
▶ Can This 2015 Medical IPO Inject New Life Into Its Stock?   [12:03PM  Investor's Business Daily]
▶ Glaukos beats Street 1Q forecasts   [May-03-17 07:27PM  Associated Press]
▶ Glaukos Corp. Value Analysis (NYSE:GKOS) : May 1, 2017   [May-01-17 04:59PM  Capital Cube]
Financial statements of GKOS
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.